BioCryst Pharmaceuticals, Inc. cash flow to debt ratio of 75.17% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

BioCryst Pharmaceuticals, Inc.'s free cash flow has increased -716.08% from $-53.14M last year to $327.41M, signaling increasing performance

BioCryst Pharmaceuticals, Inc.'s debt to equity ratio is -0.90, signaling that the company spent its equity and risk bankruptcy.

BioCryst Pharmaceuticals, Inc.'s debt to equity ratio is -0.90, signaling that the company spent its equity and risk bankruptcy.

BioCryst Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.47x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

BioCryst Pharmaceuticals, Inc.'s interest coverage ratio is -4.16, which means that the company struggles to meet interest obligations, signaling financial risk.

BioCryst Pharmaceuticals, Inc.'s profit margin has decreased (107.38%) in the last year from -19.72% to -40.90%, signaling decreasing performance

BioCryst Pharmaceuticals, Inc.'s short-term assets of $404.35M exceed its short-term liabilities of $196.07M

BioCryst Pharmaceuticals, Inc.'s return on assets of -68.96% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioCryst Pharmaceuticals, Inc.'s return on equity of 101.55%, is higher than 15.00%, indicating good performance

BioCryst Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

BioCryst Pharmaceuticals, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

BioCryst Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

BioCryst Pharmaceuticals, Inc. has a free cash flow yield of 13.09%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

BioCryst Pharmaceuticals, Inc.'s yearly earnings has increased -396.87% since last year from $-88.88M to $263.86M, signaling increasing performance

BioCryst Pharmaceuticals, Inc.'s yearly revenue has increased 94.10% since last year from $450.71M to $874.84M, signaling increasing performance

ROIC -88.96% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioCryst Pharmaceuticals, Inc.'s 3-year revenue CAGR of 47.82% is positive, indicating growing revenue over the past 3 years

BioCryst Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

BioCryst Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

BioCryst Pharmaceuticals, Inc. has insufficient data to evaluate this check.

BioCryst Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioCryst Pharmaceuticals, Inc. is overvalued relative to its fair value price of 9.75 based on EBITDA multiple model

BioCryst Pharmaceuticals, Inc. has an EV/EBITDA ratio of 7.67x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

BioCryst Pharmaceuticals, Inc. is overvalued relative to its fair value price of -24.24 based on Earnings Fair Value model

BioCryst Pharmaceuticals, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

BioCryst Pharmaceuticals, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

BioCryst Pharmaceuticals, Inc. has a price-to-sales ratio of 2.66x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue